Telomir Pharmaceuticals (TELO) Net Equity Issued and Repurchased (2023 - 2026)

Telomir Pharmaceuticals has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $4.5 million in Q3 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $4.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.5 million (down 7.1% YoY) and the FY2024 annual result came in at $6.8 million, up 583.3% from the prior year.
• Net Equity Issued and Repurchased rose to $4.5 million in Q3 2025 per TELO's latest filing, from $1.0 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $5.8 million in Q1 2024 and troughed at -$90000.0 in Q2 2023.
• A 3-year average of $2.1 million and a median of $1.0 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 1011.11% in 2024, down 483.3% in 2024.
• Over 3 years, Net Equity Issued and Repurchased stood at $90000.0 in 2023, then soared by 1011.11% to $1.0 million in 2024, then jumped by 350.22% to $4.5 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $4.5 million, $1.0 million, and $5.8 million for Q3 2025, Q4 2024, and Q1 2024 respectively.